Review Article

Middle Cerebral Artery Occlusion Model in Rodents: Methods and Potential Pitfalls

Fudong Liu¹ and Louise D. McCullough¹, ²

¹ Department of Neuroscience, University of Connecticut Health Center, Farmington, CT 06030, USA
² Department of Neurology, University of Connecticut Health Center and The Stroke Center at Hartford Hospital, 263 Farmington Avenue, Farmington, CT 06030, USA

Correspondence should be addressed to Louise D. McCullough, lmccullough@uchc.edu

Received 15 September 2010; Revised 23 December 2010; Accepted 23 December 2010

A variety of animal models have been developed for modeling ischemic stroke. The middle cerebral artery occlusion (MCAO) model has been utilized extensively, especially in rodents. While the MCAO model provides stroke researchers with an excellent platform to investigate the disease, controversial or even paradoxical results are occasionally seen in the literature utilizing this model. Various factors exert important effects on the outcome in this stroke model, including the age and sex of the animal examined. This paper discusses emerging information on the effects of age and sex on ischemic outcomes after MCAO, with an emphasis on mouse models of stroke.

1. Introduction

Stroke is the third major cause of mortality and the leading cause of long-term disability in the United States. Ischemic stroke accounts for approximately 80% of all strokes [1]; however, only one FDA-approved therapy exists for treatment of acute ischemic stroke, the thrombolytic tissue plasminogen activator (tPA) [2]. In order to investigate the mechanisms underlying injury after ischemic stroke as well as to develop effective therapeutic approaches to the disease, several ischemic stroke models have been developed in a variety of species, including rodents, canines, rabbits, cats, and even nonhuman primates [3–6]. Models of stroke that can be used in rodents are becoming increasingly popular at bench because (1) genetically-engineered mice are particularly useful for furthering our understanding of components of ischemic pathophysiology and in designing potential new preventative, neuroprotective, and therapeutic drugs and interventions; (2) a number of neurosensory and motor behavior outcomes have become standardized for rodents, which facilitates the assessment of functional outcomes after experimental stroke [7]; (3) the public tends to have fewer animal welfare concerns regarding rodents in research compared to nonrodents [7–10]. In general, there are four major types of animal models of ischemic stroke: (1) complete global cerebral ischemia; (2) incomplete global ischemia; (3) focal cerebral ischemia and (4) Multifocal cerebral ischemia [10] (Figure 1). Since ischemic stroke in patients usually results from a thrombotic or embolic occlusion in a major cerebral artery, most often the middle cerebral artery (MCA), experimental focal cerebral ischemia models have been developed to mimic human stroke and serve as an indispensable tool in the stroke research field [11].

However, all experimental models of disease have weaknesses and stroke modeling is no exception, especially with the reliance on rodent models. Despite many promising pharmacological agents that dramatically reduce tissue injury after experimental stroke at the bench, none have been translated to efficacious agents for clinical use. Possible reasons for this “lack of translation” have been recently reviewed elsewhere [12, 13], but some of the most obvious but frequently ignored factors will be discussed here, that is, the effect of age and sex on stroke outcomes. Most experimental stroke studies have been done exclusively in young male animals, although stroke is a disease that mainly affects the elderly [14]. Stroke is also sexually dimorphic
in clinical populations with different functional outcomes, age of onset, and etiologies in men and women [15]. We will describe the most commonly used models in the investigation of stroke in rodents, with a focus on the MCAO model, and discuss some of the limitations of this model as it is currently used. Several common factors that can influence histological and behavioral outcomes including aging and sex/hormonal factors will also be discussed.

2. Modeling Stroke: MCAO Model

Four major rodent models of focal cerebral ischemia have been developed: (1) models not requiring craniotomy (embolic model, intraluminal suture MCAO model, photothrombosis model, and endothelin-1-induced stroke model), (2) models requiring craniotomy (Tamura’s model), (3) posterior cerebral circulation stroke models, and (4) cerebral venous thrombosis models. These have been the subject of an excellent comprehensive review [11] and will not be discussed here except for the intraluminal model. Among these well-developed models, MCAO is widely used and has been extended to the mouse in recent genetic studies of cell death mechanisms. This model offers a simpler and less traumatic surgical approach compared with craniotomy models, lends itself more readily to the study of reperfusion and has been adapted for use in continuous magnetic resonance imaging [16], produces focal occlusion of a large cerebral artery as seen in human stroke, and can be done in a high-throughput manner [17]. Rigorous control of temperature, physiological variables, and assessment of occlusion with noninvasive means (i.e., Laser Doppler) reduces variability.

2.1. Infarct Size Induced by MCAO. The reversible MCAO model has been well studied and utilized by stroke researchers due to its clinically relevant nature that mimics recanalization of an embolized or thrombosed vessel by tPA (Figure 2). Although the model has been employed to study ischemic stroke for decades, the evolution of infarct within the area blood supplied by MCA has not been well elucidated. Therefore significant controversy exists due to the variability of final infarct size and debate as to the most reliable time point to measure the effects of various therapeutic agents [9, 18, 19]. Generally speaking, infarct development appears to be more rapid in mice than in rats as well as in reperfusion versus permanent “nonreperfusion” MCAO models. Previous studies have demonstrated an increase in infarct volumes even as late as 3d after stroke in rats [20, 21]; however these animals had no restoration of blood flow which may delay infarct development. In a previous study [16] we have shown that 90-minute occlusion of the MCA induces a peak volume of injury as delineated by TTC staining by 24 h in mice which remains unchanged through day 7 of reperfusion (Figure 3). We also observed a spatiotemporal evolution of core and penumbra: at earlier time points (2 and 6 hours after occlusion), the histological infarct core, as measured by TTC, is limited to the striatum, and the viable tissue surrounded this core and included much of the cortex. Subsequently the “TTC-defined” core expands to involve most of the cortical tissue supplied by the MCA. This occurs quite rapidly and is complete (by TTC) within 6–12 hours after stroke onset. It is unclear if any intervention begun several hours after ischemic onset can reduce recruitment of the penumbra. Certainly by 12 hours, all of the territory supplied by the MCA is irreversibly damaged. Studies with MRI in rat models of transient
MCAO [22, 23] demonstrated that stroke-induced infarct evolved into an area of injury of similar magnitude to the initial diffusion disturbance by 24 h as measured by a reduced apparent diffusion coefficient and prolonged T2 signals. Several previous studies have also revealed that apoptosis induced by transient MCAO model reached its peak at 24–48 h of stroke [24, 25]. In murine reperfusion models, increases in T2 signal were seen extremely early (by 90 minutes) in the infarct area, indicative of edema and breakdown of the blood-brain barrier, which were not seen after permanent occlusion. This suggests that reperfusion may accelerate infarct development, at least in mice [26]. The dynamics of the penumbra are also different between strains, as measured by MRI [27]. The spontaneously hypertensive rat and its stroke-prone cohort develop larger and much less variable infarcts following MCAO [28]. The rapid evolution of the penumbra does emphasize one of the limitations in clinical neuroprotection studies. Most animal studies have administered a putative neuroprotective agent either pre-ischemia, intraischemia, or very soon after reperfusion [29–31], time windows that are impossible to mimic in clinical trials. Although a prolonged “therapeutic window” does allow for a greater number of patients to be treated, it is unlikely that salvageable tissue is present, especially after successful reperfusion if it occurs after 8 hours. Attempting to treat patients without radiographic evidence of penumbral tissue after 6 hours is likely an exercise in futility and dilutes any potential benefit of an acute
neuroprotective agent. Other mechanisms that predominate after injury, such as inflammation, may be more viable targets [32].

Interestingly, different histological staining methods reveal different evolving patterns of infarct tissue or degenerating neurons. Each method has advantages and disadvantages. For example, while TTC staining of MCAO-induced brain injury demonstrated no further enlargement of infarct after 24 h of stroke, Fluoro-Jade B [33] staining showed neuronal degeneration peaked at 24 h, increased by 48 hours but decreased to baseline values by 7 d after stroke [16]. This suggests that Fluoro-Jade B is a more sensitive marker for acute neuronal degeneration but may not be as useful for assessment of chronic damage, which is more accurately performed with cresyl violet (CV). TTC is a marker of tissue dehydrogenase and mitochondrial dysfunction and may not represent irreversible cell death, therefore it may overestimate infarct size [34]. Longer-term assessment of infarct also suggests that damage, as measured by acute TTC staining, overestimates the degree of injury. 50% of the ischemic hemisphere is poorly stained by TTC acutely, but at 30 days, only 10–20% of the hemispheric volume is lost (unpublished observations). This suggests that TTC may not reliably reflect tissue death, but rather tissue dysfunction. Fluoro-Jade B is very specific for neuronal death but becomes non-specific for irreversible damage, therefore it is unlikely to reliably reflect tissue death, but rather tissue dysfunction. Fluoro-Jade B staining is more sensitive to neuronal death but becomes non-specific for irreversible cell death, therefore it is unlikely to reliably reflect tissue death, but rather tissue dysfunction. Fluoro-Jade B is very specific for neuronal death but becomes non-specific for irreversible cell death, therefore it is unlikely to reliably reflect tissue death, but rather tissue dysfunction.

2.2. Modeling Stroke Risk Factors. Increased stroke risk factors are major contributing factors to the rising prevalence of stroke and include hypertension, obesity, and diabetes [35]. Models for these important risk factors have been developed. For example, the APO E-deficient (apoE−/−) mouse, established in 1992, is one of the most important animal models of atherosclerosis [36]. Spontaneously hypertensive (SH) rats are utilized as a “stroke-prone” animal model and widely used in hypertension studies [37]. Mutation of cystathionine β-synthetase (CBS), which induces enhanced atherothrombosis [38], has also been investigated. Although modeling stroke risk factors has advanced our knowledge of these disorders, the interaction with age and sex has been frequently ignored.

3. Effect of Age on Modeling MCAO

Aging is the most important independent risk factor for stroke. Older patients have higher in-hospital mortality as well as poorer functional outcomes after an ischemic event [14]. Although age is one of the most significant prognostic markers for poor outcome [39], very few studies have been performed in aged animals, especially in animals over 15 months of age. Numerous neurochemical and physiological changes occur with aging [40]. Aging animals have less edema formation after stroke compared to the young [41], and NKCC, a Na-K-Cl cotransporter, is expressed at a lower level in aging mice than in young mice after MCAO [42], suggesting a possible mechanism for this finding. Clinical postmortem studies [43] also confirmed more robust edema formation in the young brain after stroke and is in part the rationale for proposing an upper age limit of 60 for hemicranectomy [44]. Recent data suggests that ischemic preconditioning is less effective in the aged heart in both experimental and clinical studies [45], and our study also found that Compound C, adenosine monophosphate-activated protein kinase (AMPK) inhibitor which has been proved to be neuroprotective in young animals after MCAO [46, 47], has no effect in aging animals (manuscript submitted). The continued clinical failure of promising neuroprotective agents [48] has led us to question the appropriateness of modeling stroke in young animals. New paradigms for conducting translational research in aging animals are urgently needed.

It is far more difficult to perform MCAO in aging rodents. Aging animals are usually heavier with higher amounts of visceral fat, are less tolerant to anesthesia, and have less flexible vessels making insertion of occluding sutures much more difficult than in young animals. Aging animals have higher mortality after MCAO due to frailty, peripheral immunesupression, and other comorbid diseases [41]. Stroke researchers frequently avoid using aging animals for MCAO due to the more complex surgical procedure and high cost of purchasing and raising animals. Very few experimental studies exist in the literature that have examined middle aged and aging animals, and these have led to somewhat inconsistent results. Kharlamov et al. [49] found no difference in infarct size at 24 hours when male Fisher rats of three different age groups (4, 20, and 27 months old) were evaluated. In another study, age was associated with an increase in infarct size from 9 to 12% in the neocortex and striatum in aged male Wistar rats [50]. In contrast, other studies have suggested that histological infarct damage may be paradoxically higher in young (3 months) compared to old (24–26 months) male rats [51]. Many of the studies that have shown an age-related increase in stroke volume used female animals (as they are smaller than age-matched males), and findings may also be related to the loss of ovarian hormones with aging [52]. Our previous studies have definitively shown that aging male mice have significantly smaller infarcts than young males after 24 h of 90-minute MCAO [41], at least at the histological level. This difference can be detected even as long as 30 d after MCAO (unpublished data). In spite of the disagreements between the histological effects of aging on infarct volume (with some showing larger and others showing smaller infarct injury), invariably significantly higher mortality rates and more severe neurological impairments are found in the older animals. For example, one study that examined 3–4 month versus 22–24-month-old male rats demonstrated a mortality rate of 43.5% in aged rats compared to 9% in the young [53]. Despite the fact that the mortality risk from the ischemic damage is greater for old mice, we have found that eventual recovery (4 weeks after stroke) is not different from that of
a young mouse in most simple behavioral tests, although the “slope” of recovery is much slower. An exception is the corner test (manuscript submitted). The correlation between brain damage, behavioral recovery, and age needs to be further investigated.

Given that young and aging animals are usually of different weights at the time of MCAO, it is not surprising that the cerebral vessels are also of different size and dimension. To ensure adequate and equivalent levels of cerebral blood flow (CBF) reduction, we have utilized different sizes of occluding sutures in young and aging mice. We have found that in young mice (20 ~ 25 mg), successful occlusion requires a 0.21 mm suture, but in aging mice (30 ~ 40 mg), a larger 0.23 mm suture is required to obtain the same degree of CBF reduction. Our experience emphasizes the importance of routine laser Doppler blood flow monitoring to ensure adequate (85% drop from prestroke baseline) in murine MCAO models. This not only reduces variability but also ensures that each animal experiences the same level of cerebral ischemia, as this can have dramatic effects on outcomes. Several other issues need to be considered when utilizing aging animals in research, including the higher rates of infections and malignancy.

4. Effect of Sex on Modeling MCAO

It is increasingly recognized that the epidemiology of ischemic stroke is sexually dimorphic [15], and therapeutic agents aimed at stroke function differently in male and female subjects. For example, anticoagulated women had a relative risk of 2.0 for ischemic stroke versus anticoagulated men [54], suggesting sex differences in coagulation. Women experience a greater benefit from tissue plasminogen activator (tPA) treatment than men [55]. Clinical trials of the 21-aminosteroid lipid peroxidation inhibitor tirilazad conducted in traumatic brain injury, subarachnoid hemorrhage, ischemic stroke, and spinal cord injury indicated that the beneficial effect of tirilazad was greater in males than females [56, 57]. These sex differences are becoming increasingly apparent in clinical populations. The vast majority of preclinical studies also continue to exclusively use male animals. There are significant limitations to this approach, as we discuss here, utilizing estrogen (E2) as an example. Prior to menopause, women have a lower risk of stroke relative to age-matched men [58]. After menopause, the incidence of stroke in women increases [59], coincident with the diminished circulating levels of estrogen and progesterone and surpasses that of men. Therefore, this pattern of stroke risk has been attributed to the presence of protective female sex hormones. Over the past thirty years, the majority of cohort, retrospective, or prospective observational studies have demonstrated significant reductions in cardiovascular disease in postmenopausal women receiving E2 (ERT) or combined estrogen-progesterone therapy (HRT) [60]. A growing number of preclinical studies have also documented sexual dimorphism in stroke. Female rats and mice of many different inbred and outbred strains sustain smaller tissue damage for an equivalent insult from focal or global cerebral ischemia [61]. The “female-protected” phenotype can often be reversed by inducing surgical menopause via ovariectomy, and protection can be recapitulated in male animals by administration of exogenous estrogens [62]. E2 has neurotrophic, antiapoptotic, vasodilatory, anti-inflammatory, and antioxidant effects, each of which could contribute to improved outcome in the brains of males and females [63]. E2 treatment at physiological relevant concentrations reduces infarction after MCAO in ovariectomized (OVX) or reproducitively senescent female animals [64, 65], as well as in males [61, 66], even when given after MCAO [62].

The Woman’s Health Initiative (WHI), the largest clinical trial of E2 replacement for stroke prevention, showed a surprising increase in stroke incidence in estrogen-treated women [67, 68]. The explanation for these findings has been debated extensively in the literature [67] but is thought to be due to the unexpected proinflammatory effects of estrogen administration after a long period of “hypoestrogenemia”. A recent study in mice demonstrated that prolonged loss of E2 prior to replacement (10 weeks) ameliorated the neuroprotective and anti-inflammatory effects of E2 seen in MCAO-model [69]. It appears that timing of estrogen replacement after the menopause is critical to outcome in both animal models and clinical trials. Women involved in the WHI trial were considerably older (average age of 63) and well past menopause (which occurs at an average age of 51) prior to randomization [70, 71]. In the Northern Manhattan Stroke Study, stroke rates in women do not equalize to those of men until beyond 75 years of age suggesting that considerable time passes before females lose the protection of gonadal steroids.

In addition to the timing of E2 replacement, other factors may also affect the effects of E2 in MCAO induced brain injury, including dosing, the age of the animal, and the timing of replacement. A recent study [72] administering 17β-estradiol to OVX rats that underwent MCAO found that slow-release commercially purchased pellets of 17β-estradiol produced an early supraphysiological peaks followed by a substantial decrease in serum levels of E2, while silastic capsules (inner/outer diameter: 1.575/3.175 mm) yielded 17β-estradiol concentrations within the physiological range for at least 4 weeks. The former was detrimental and exacerbated brain injury, whereas the latter was beneficial in reducing MCAO-induced brain damage. The stroke model itself may also exert an influence on the effect of E2 treatment. Although most studies with transient MCAO confirmed the neuroprotective effect of E2 replacement [63], 17β-estradiol treatment following permanent MCAO did not improve stroke outcomes; however commercial pellets were used, and supraphysiological levels of E2 could account for this discrepancy [73].

Interestingly, it is becoming increasingly accepted that the effect of sex on stroke outcome may also be hormone independent. Innate sex differences also contribute to the variability of infarct volumes induced by MCAO in male and female animals. It is increasingly recognized that different cell death pathways may predominate, respectively, in male and female subjects exposed to ischemic injury [74] (Figure 4). Cytochrome C-caspase pathway was found...
to be the predominant cell death pathway in females after ischemic insults [31, 75]. Administration of broad spectrum caspase inhibitor, quinoline-Val-Asp(Ome)-CH2-O-phenox (Q-VD-OPh), decreased infarct volumes in OVX female mice after MCAO but had no effect in males [31]. On the other hand, PARP-1-AIF pathway mediates cell death induced by ischemic insults mainly in male animals [76, 77]. The PARP-1 inhibitor minocycline is neuroprotective in male mice but not in OVX females after MCAO [78], which awaits confirmation. Aging female mice exhibited larger infarct volumes than aging males after 24 h of 90-minute MCAO, although the serum levels of E2 were equivalently low in both aging males and females [41]. Female rats are more vulnerable to the long-term consequences of neonatal inflammatory injury compared to neonatally injured males [79].

The sexual dimorphism seen in MCAO in aging animals may also be due to differing inflammatory responses to stroke in aging males and females. A growing body of evidence suggests that sexual dimorphism exists in the inflammatory response and even in the frequency of pro/anti-inflammatory gene variants [80]. Leukocyte function varies by sex in aging rats; aging males are less immune competent than age-matched females as females showed higher lymphoproliferative responses, higher Natural Killer activity, and higher IL-2 release in the spleen and axillary nodes [81]. In previous studies in aging mice, [41] we found that the serum levels of IL-6, a potent proinflammatory cytokine [82, 83], were lower in aging males than in aging females after MCAO. Indeed, these sex differences can also be recapitulated in neonatal animals [75], where circulating hormone levels are equivalent [84]. All these studies suggested that sex is an independent viable that must be addressed in translational stroke studies if we hope to develop efficacious neuroprotective agents from our animal models. Sex differences in stroke must be considered as an independent viable when interpreting results from either experimental or clinical trials for neuroprotective agents.

In summary, the MCAO model in rodents provides a useful tool to stroke researchers; nevertheless, timing of analysis, animal age, and sex are important factors that have major effects on stroke outcome but continue to be less studied. We must keep in mind these influential factors when designing our experiments and in our attempts to translate therapies into the clinical populations at the highest risk for stroke, women and the elderly.

Acknowledgment

This work was supported by the NIH/NINDS (Grants NS050505 and NS055215 to L. D. McCullough).
References


